DCTD Programs
FOLLOW DCTD2023 News
Cancer, Aging, and Comorbidities Workshop; January 25-July 14, 2023
Date: August 28, 2023
Source: DCTD Meetings
NCI’s ComboMATCH initiative will test new drug combinations guided by tumor biology
Date: June 1, 2023
Source: NCI Press Release
Date: June 13, 2023
Source: DTP Website
Blinatumomab increases survival for infants with an aggressive type of ALL
Date: June 8, 2023
Source: NCI Cancer Currents
Drug regimen boosts survival of people with advanced colorectal cancer
Date: May 24, 2023
Source: NCI Cancer Currents
Rare melanoma very likely to respond to treatment with pembrolizumab
Date: May 5, 2023
Source: NCI Cancer Currents
Nirogacestat may offer hope to people with desmoid tumors
Date: May 1, 2023
Source: NCI Cancer Currents
Transforming cancer clinical trials for better, fast results
Date: May 1, 2023
Source: NCI Cancer Currents
Immunotherapy’s role in treating endometrial cancer expected to grow
Date: April 12, 2023
Source: NCI Cancer Currents
Liquid biopsies on the horizon for children with solid cancers
Date: April 11, 2023
Source: NCI Cancer Currents
Schedule of DCTD Presentations at ASCO 2023
Posted May 30, 2023
Source: DCTD News
Posted May 23, 2023
Source: DCTD Meetings
Posted April 12, 2023
Source: NCI Press Release
2023 American Association for Cancer Research Annual Meeting; Schedule of DCTD Presentations
Posted March 29, 2023
Source: DCTD News
Posted March 27, 2023
Source: DCTD Meetings
Preventing Resistance to Cancer Targeted Therapies
Posted March 17, 2023
Source: NCI Cancer Currents Blog
Tucatinib Approved for HER2-Positive Colorectal Cancer
Posted February 10, 2023
Source: NCI Cancer Currents Blog
Blinatumomab Extends Life for People with ALL in Remission
Posted January 25, 2023
Source: NCI Cancer Currents Blog
Kisqali Plus Hormone Therapy for Metastatic Breast Cancer
Posted January 11, 2023
Source: NCI Cancer Currents Blog